Oncology Drugs

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Powered Research will unveil an AI that speeds drug testing for retinal diseases and key findings on animal models, aiming to transform preclinical studies.

With late-stage trials for two common eye conditions affecting millions, Cloudbreak Pharma is advancing novel drops where no approved drugs exist.

A Swiss biotech's novel antibiotic has entered human trials with new funding, offering a fresh hope against the world's most dangerous superbugs.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

With a multi-billion dollar track record of IPOs and acquisitions, the veteran CEO's appointment signals Frazier's focus on navigating complex markets.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

Taiwan's PharmaEssentia is building a new U.S. facility in Puerto Rico, a move set to bolster drug supply chains and deepen US-Taiwan economic ties.

With FDA clearance for clinical trials, CanWell Pharma’s novel CAN016 ADC brings a two-pronged attack against drug-resistant HER2-positive cancers.

With a new patent for its drug ALPHA-1062, Alpha Cognition may become a first-mover in the $14 billion traumatic brain injury market, which has no approved therapies.

A novel transdermal curcumin gel shows significant pain reduction in a clinical trial, offering a potential non-oral alternative for millions with knee pain.

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

With a key data readout looming for its chronic cough drug, Nocion adds a renowned dealmaker to its board, fueling speculation of a potential acquisition.

A new investigation shows drug companies make $31 in profit for every $1 paid in penalties, suggesting fines are just a cost of doing business.